Prevnar 7 to Prevnar 13 (2000–2010)
Wyeth launched Prevnar 7, the first pneumococcal conjugate vaccine, in 2000. Ten years later it rolled out Prevnar 13, covering 13 serotypes instead of 7. Pfizer, which bought Wyeth in 2009, turned the franchise into a multibillion-dollar seller.
Prevnar 13 captured nearly the entire pediatric and adult pneumococcal vaccine market.
The move established broader serotype coverage as the central competitive lever in pneumococcal vaccines.
Vaxcyte is extending that logic: VAX-31 covers 31 serotypes versus 20 for Prevnar 20 and 21 for Capvaxive.
